Plasma somatostatin and vasoactive intestinal polypeptide responses to an oral mixed test meal in obese patients. 1989

T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
Scientific Institute of Internal Medicine, University of Genoa, Italy.

Ten obese and 10 control subjects were studied in basal conditions and after ingestion of a standard mixed test meal. Blood glucose, insulin, somatostatin (SLI) and vasoactive intestinal polypeptide (VIP) concentrations were determined before and 30, 60, 90, 120, 180 and 240 min after the start of the meal. Basal SLI levels in the obese (14.4 +/- 0.7 ng/l) were not significantly different from those in the controls (15.5 +/- 0.8 ng/l), whereas after the meal a blunted secretory response was recorded. Baseline plasma VIP levels were higher in the obese (29.7 +/- 1.5 ng/l) than in the control subjects (19.8 +/- 1.3 ng/l) and, similarly to the controls, were unaffected by meal ingestion. Data suggest that in the course of obesity an enhanced VIP secretion in association with a diminished SLI responsiveness to meals occurs.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005502 Food Substances taken in by the body to provide nourishment. Foods
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone
D014660 Vasoactive Intestinal Peptide A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE). VIP (Vasoactive Intestinal Peptide),Vasoactive Intestinal Polypeptide,Vasointestinal Peptide,Intestinal Peptide, Vasoactive,Intestinal Polypeptide, Vasoactive,Peptide, Vasoactive Intestinal,Peptide, Vasointestinal,Polypeptide, Vasoactive Intestinal

Related Publications

T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
June 1984, Scandinavian journal of clinical and laboratory investigation,
T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
January 1979, Scandinavian journal of gastroenterology,
T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
January 1978, Scandinavian journal of gastroenterology,
T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
November 1980, Gastroenterology,
T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
April 1978, Experientia,
T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
January 1991, Gastroenterology,
T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
July 1983, Cancer,
T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
February 1986, Acta chirurgica Scandinavica,
T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
August 1987, Life sciences,
T Barreca, and R Franceschini, and V Messina, and A Cataldi, and M Salvemini, and E Rolandi
November 1984, Neuroscience letters,
Copied contents to your clipboard!